Pathogen reduction for DoD
This article was originally published in The Gray Sheet
Executive Summary
Navigant Biotechnologies receives $2 mil. from the U.S. Department of Defense for development of Mirasol riboflavin-based pathogen reduction technology for red blood cells. The funding was included in DoD's 2004 $317.2 bil. budget, signed Sept. 30. Walter Reed Army Institute of Research will participate in development of Mirasol, which is slated to enter Phase I trials in early 2004 (1"The Gray Sheet" Sept. 8, 2003, p. 14)...
You may also be interested in...
Navigant Pathogen Inactivation System Catching Up With Cerus, Vitex
Navigant Biotechnologies is dedicating $10 mil. in 2004 to the development of its Mirasol riboflavin-based pathogen reduction technology (PRT) for platelets and red blood cells
Cerus Pathogen Inactivation Trial Delay Alters Landscape For Vitex, Navigant
Uncertainty over Baxter/Cerus' Intercept red blood cell pathogen reduction program may benefit competitor Vitex, which is pursuing the same indication for its Inactine device
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.